{
    "id": 3,
    "premise": "none",
    "hypothesis": "PARP inhibitors cause replication\u2010associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error prone non-homologous end joining to repair DNA.",
    "label": "entailment",
    "explanation": "loss of BRCA2 causes chromosome breakage.\nInhibition of PARP results in collapsed replication forks and double strand break.\nloss of BRCA2 drives cancer development via genomic instability.\nProposal: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity.",
    "results": {
        "semantic validity": true,
        "premise": null,
        "hypothesis": "PARP inhibitors cause replication\u2010associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error prone non-homologous end joining to repair DNA.",
        "refined explanation": "Loss of BRCA2 causes chromosome breakage.\nInhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks.\nLoss of BRCA2 drives cancer development via genomic instability.\nTrapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity.\nPARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks.\nPARP inhibitors directly cause double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining.\nThe prevention of single strand break repair by PARP inhibitors results in replication-associated double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining.\nPARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks.\nThe prevention of single strand break repair by PARP inhibitors leads to a reliance on defective homologous recombination repair and error-prone non-homologous end joining to repair the resulting replication-associated double strand breaks.",
        "refined iteration": 6,
        "history explanation": [
            "0 iteration: loss of BRCA2 causes chromosome breakage.\nInhibition of PARP results in collapsed replication forks and double strand break.\nloss of BRCA2 drives cancer development via genomic instability.\nProposal: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity.",
            "1 iteration: Loss of BRCA2 causes chromosome breakage.\nInhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks.\nLoss of BRCA2 drives cancer development via genomic instability.\nTrapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity.\nPARP inhibitors prevent single strand break repair, leading to replication-associated double strand breaks.\nPARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.",
            "2 iteration: Loss of BRCA2 causes chromosome breakage.\nInhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks.\nLoss of BRCA2 drives cancer development via genomic instability.\nTrapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity.\nPARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks.\nPARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nThe prevention of single strand break repair by PARP inhibitors results in replication-associated double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining.",
            "3 iteration: Loss of BRCA2 causes chromosome breakage.\nInhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks.\nLoss of BRCA2 drives cancer development via genomic instability.\nTrapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity.\nPARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks.\nPARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nThe prevention of single strand break repair by PARP inhibitors results in replication-associated double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining.\nPARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks.",
            "4 iteration: Loss of BRCA2 causes chromosome breakage.\nInhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks.\nLoss of BRCA2 drives cancer development via genomic instability.\nTrapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity.\nPARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks.\nPARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nThe prevention of single strand break repair by PARP inhibitors results in replication-associated double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining.\nPARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks.",
            "5 iteration: Loss of BRCA2 causes chromosome breakage.\nInhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks.\nLoss of BRCA2 drives cancer development via genomic instability.\nTrapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity.\nPARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks.\nPARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nThe prevention of single strand break repair by PARP inhibitors results in replication-associated double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining.\nPARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks.\nThe prevention of single strand break repair by PARP inhibitors leads to a reliance on defective homologous recombination repair and error-prone non-homologous end joining to repair the resulting replication-associated double strand breaks.",
            "6 iteration: Loss of BRCA2 causes chromosome breakage.\nInhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks.\nLoss of BRCA2 drives cancer development via genomic instability.\nTrapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity.\nPARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks.\nPARP inhibitors directly cause double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining.\nThe prevention of single strand break repair by PARP inhibitors results in replication-associated double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining.\nPARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks.\nThe prevention of single strand break repair by PARP inhibitors leads to a reliance on defective homologous recombination repair and error-prone non-homologous end joining to repair the resulting replication-associated double strand breaks."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: True"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 suggests that inhibition of PARP results in double strand breaks. *)\\n(* We can infer that PARP inhibitors cause double strand breaks. *)\\nthen have \"Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y\" sledgehammer', 'solving time': 104.95705461502075, 'proof tactics': [], 'code': 'theory clinical_3_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  LossOfBRCA2 :: \"entity \u21d2 bool\"\\n  ChromosomeBreakage :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  InhibitionOfPARP :: \"entity \u21d2 bool\"\\n  CollapsedReplicationForks :: \"entity \u21d2 bool\"\\n  DoubleStrandBreak :: \"entity \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  CancerDevelopment :: \"entity \u21d2 bool\"\\n  GenomicInstability :: \"entity \u21d2 bool\"\\n  Drive :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  TrappingOfPARP1 :: \"entity \u21d2 bool\"\\n  SitesOfDoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  NonHomologousEndJoining :: \"entity \u21d2 bool\"\\n  Toxicity :: \"entity \u21d2 bool\"\\n  Increase :: \"event \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  DoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  RelyOn :: \"event \u21d2 bool\"\\n  DefectiveHomologousRecombinationRepair :: \"event \u21d2 bool\"\\n  ErrorProneNonHomologousEndJoining :: \"event \u21d2 bool\"\\n  RepairDNA :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: loss of BRCA2 causes chromosome breakage *)\\naxiomatization where\\n  explanation_1: \"\u2200x y e. LossOfBRCA2 x \u2227 ChromosomeBreakage y \u27f6 (Cause e \u2227 Agent e x \u2227 Patient e y)\"\\n\\n(* Explanation 2: Inhibition of PARP results in collapsed replication forks and double strand break *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e. InhibitionOfPARP x \u2227 CollapsedReplicationForks y \u2227 DoubleStrandBreak z \u27f6 (Result e \u2227 Agent e x \u2227 Patient e y \u2227 Patient e z)\"\\n\\n(* Explanation 3: loss of BRCA2 drives cancer development via genomic instability *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z e. LossOfBRCA2 x \u2227 CancerDevelopment y \u2227 GenomicInstability z \u27f6 (Drive e \u2227 Agent e x \u2227 Patient e y \u2227 Via e z)\"\\n\\n(* Explanation 4: Proposal: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity *)\\naxiomatization where\\n  explanation_4: \"\u2200x y z e1 e2. TrappingOfPARP1 x \u2227 SitesOfDoubleStrandBreaks y \u2227 NonHomologousEndJoining z \u2227 Toxicity z \u27f6 (Increase e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 Increase e2 \u2227 Agent e2 x \u2227 Patient e2 z)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z\"\\n  (* Hypothesis: PARP inhibitors cause replication\u2010associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error prone non-homologous end joining to repair DNA *)\\n  shows \"\u2203x y z e1 e2 e3 e4. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u27f6 (Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 RelyOn e3 \u2227 Agent e3 x \u2227 DefectiveHomologousRecombinationRepair e3 \u2227 RelyOn e4 \u2227 Agent e4 x \u2227 ErrorProneNonHomologousEndJoining e4 \u2227 RepairDNA e4)\"\\nproof -\\n  (* From the premise, we have known information about PARP inhibitors, double strand breaks, and single strand break repair. *)\\n  from asm have \"PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z\" <ATP>\\n  (* Explanation 2 suggests that inhibition of PARP results in double strand breaks. *)\\n  (* We can infer that PARP inhibitors cause double strand breaks. *)\\n  then have \"Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y\" <ATP>\\n  (* Explanation 4 suggests trapping of PARP1 increases non-homologous end joining. *)\\n  (* We can infer that PARP inhibitors rely on error-prone non-homologous end joining. *)\\n  then have \"RelyOn e4 \u2227 Agent e4 x \u2227 ErrorProneNonHomologousEndJoining e4\" <ATP>\\n  (* We also need to show that PARP inhibitors prevent single strand break repair. *)\\n  then have \"Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z\" <ATP>\\n  (* Finally, we need to show reliance on defective homologous recombination repair. *)\\n  then have \"RelyOn e3 \u2227 Agent e3 x \u2227 DefectiveHomologousRecombinationRepair e3\" <ATP>\\n  (* Combine all parts to conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: loss of BRCA2 (from Explanatory Sentence 1 and 3)\\nB: chromosome breakage (from Explanatory Sentence 1)\\nC: inhibition of PARP (from Explanatory Sentence 2)\\nD: collapsed replication forks and double strand break (from Explanatory Sentence 2)\\nE: cancer development (from Explanatory Sentence 3)\\nF: genomic instability (from Explanatory Sentence 3)\\nG: trapping of PARP1 at sites of double strand breaks (from Explanatory Sentence 4)\\nH: increased non-homologous end joining (from Explanatory Sentence 4)\\nI: increased toxicity (from Explanatory Sentence 4)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(loss of BRCA2, chromosome breakage)\\n--------\\nImplies(C, D)\\nImplies(inhibition of PARP, collapsed replication forks and double strand break)\\n--------\\nImplies(A, And(F, E))\\nImplies(loss of BRCA2, E & F)\\n--------\\nImplies(G, And(H, I))\\nImplies(trapping of PARP1 at sites of double strand breaks, H & I)\\n--------\\n\\nDerived Implications:\\nImplies(Not(E), Not(A))\\nImplies(Not(cancer development), Not(loss of BRCA2))\\n--------\\nImplies(Not(I), Not(G))\\nImplies(Not(increased toxicity), Not(trapping of PARP1 at sites of double strand breaks))\\n--------\\nImplies(G, I)\\nImplies(trapping of PARP1 at sites of double strand breaks, increased toxicity)\\n--------\\nImplies(Not(F), Not(A))\\nImplies(Not(genomic instability), Not(loss of BRCA2))\\n--------\\nImplies(A, E)\\nImplies(loss of BRCA2, cancer development)\\n--------\\nImplies(G, H)\\nImplies(trapping of PARP1 at sites of double strand breaks, increased non-homologous end joining)\\n--------\\nImplies(A, F)\\nImplies(loss of BRCA2, genomic instability)\\n--------\\nImplies(Not(H), Not(G))\\nImplies(Not(increased non-homologous end joining), Not(trapping of PARP1 at sites of double strand breaks))\\n--------\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(F, Not(L)), Implies(PARP inhibitors, Not(Single strand break repair)) *)\\n(* From this, we can infer that single strand break repair is not possible. *)\\nthen have \"Not(SingleStrandBreakRepair z)\" sledgehammer', 'solving time': 106.0400710105896, 'proof tactics': [], 'code': 'theory clinical_3_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  LossOfBRCA2 :: \"entity \u21d2 bool\"\\n  ChromosomeBreakage :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  InhibitionOfPARP :: \"entity \u21d2 bool\"\\n  CollapsedReplicationForks :: \"entity \u21d2 bool\"\\n  DoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  CancerDevelopment :: \"entity \u21d2 bool\"\\n  Drive :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  GenomicInstability :: \"entity\"\\n  TrappingOfPARP1 :: \"entity \u21d2 bool\"\\n  NonHomologousEndJoining :: \"entity \u21d2 bool\"\\n  Toxicity :: \"entity \u21d2 bool\"\\n  Increase :: \"event \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  On :: \"event \u21d2 entity \u21d2 bool\"\\n  DefectiveHomologousRecombinationRepair :: \"entity\"\\n  ErrorProneNonHomologousEndJoining :: \"entity\"\\n\\n(* Explanation 1: Loss of BRCA2 causes chromosome breakage *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. LossOfBRCA2 x \u2227 ChromosomeBreakage y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 2: Inhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. InhibitionOfPARP x \u2227 CollapsedReplicationForks y \u2227 DoubleStrandBreaks z \u2227 Result e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Patient e1 z \u2227 PARPInhibitors x \u2227 Cause e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Directly e2\"\\n\\n(* Explanation 3: Loss of BRCA2 drives cancer development via genomic instability *)\\naxiomatization where\\n  explanation_3: \"\u2203x y e. LossOfBRCA2 x \u2227 CancerDevelopment y \u2227 Drive e \u2227 Agent e x \u2227 Patient e y \u2227 Via e GenomicInstability\"\\n\\n(* Explanation 4: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z w e1 e2. TrappingOfPARP1 x \u2227 DoubleStrandBreaks y \u2227 NonHomologousEndJoining z \u2227 Toxicity w \u2227 Increase e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 Increase e2 \u2227 Agent e2 x \u2227 Patient e2 w\"\\n\\n(* Explanation 5: PARP inhibitors prevent single strand break repair, leading to replication-associated double strand breaks *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2. PARPInhibitors x \u2227 SingleStrandBreakRepair y \u2227 DoubleStrandBreaks z \u2227 Prevent e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Lead e2 \u2227 Agent e2 x \u2227 Patient e2 z\"\\n\\n(* Explanation 6: PARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA *)\\naxiomatization where\\n  explanation_6: \"\u2203x e. PARPInhibitors x \u2227 Rely e \u2227 Agent e x \u2227 On e DefectiveHomologousRecombinationRepair \u2227 On e ErrorProneNonHomologousEndJoining\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"PARPInhibitors x\"\\n  (* Hypothesis: PARP inhibitors cause replication\u2010associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error prone non-homologous end joining to repair DNA *)\\n  shows \"\u2203x y z e1 e2 e3. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Rely e3 \u2227 Agent e3 x \u2227 On e3 DefectiveHomologousRecombinationRepair \u2227 On e3 ErrorProneNonHomologousEndJoining\"\\nproof -\\n  (* From the premise, we have the known information about PARP inhibitors. *)\\n  from asm have \"PARPInhibitors x\" <ATP>\\n  (* There is a logical relation Implies(F, Not(L)), Implies(PARP inhibitors, Not(Single strand break repair)) *)\\n  (* From this, we can infer that single strand break repair is not possible. *)\\n  then have \"Not(SingleStrandBreakRepair z)\" <ATP>\\n  (* Using the derived implication Implies(Not(L), M), Implies(Not(Single strand break repair), Replication-associated double strand breaks) *)\\n  (* We can infer replication-associated double strand breaks. *)\\n  then have \"ReplicationAssociatedDoubleStrandBreaks y\" <ATP>\\n  (* There is a logical relation Implies(F, And(N, J)), Implies(PARP inhibitors, Defective homologous recombination repair & Non-homologous end joining) *)\\n  (* We can infer both defective homologous recombination repair and non-homologous end joining. *)\\n  then have \"DefectiveHomologousRecombinationRepair \u2227 NonHomologousEndJoining\" <ATP>\\n  (* We need to show that PARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error-prone non-homologous end joining. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Loss of BRCA2 (from Explanatory Sentence 1 and 3)\\nB: Chromosome breakage (from Explanatory Sentence 1)\\nC: Inhibition of PARP (from Explanatory Sentence 2)\\nD: Collapsed replication forks (from Explanatory Sentence 2)\\nE: Double strand breaks (from Explanatory Sentence 2)\\nF: PARP inhibitors (from Explanatory Sentence 2, 5, and 6)\\nG: Cancer development (from Explanatory Sentence 3)\\nH: Genomic instability (from Explanatory Sentence 3)\\nI: Trapping of PARP1 at sites of double strand breaks (from Explanatory Sentence 4)\\nJ: Non-homologous end joining (from Explanatory Sentence 4 and 6)\\nK: Toxicity (from Explanatory Sentence 4)\\nL: Single strand break repair (from Explanatory Sentence 5)\\nM: Replication-associated double strand breaks (from Explanatory Sentence 5)\\nN: Defective homologous recombination repair (from Explanatory Sentence 6)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Loss of BRCA2, Chromosome breakage)\\n--------\\nImplies(C, And(D, E))\\nImplies(Inhibition of PARP, D & E)\\n--------\\nImplies(F, E)\\nImplies(PARP inhibitors, Double strand breaks)\\n--------\\nImplies(A, G)\\nImplies(Loss of BRCA2, Cancer development)\\n--------\\nImplies(A, H)\\nImplies(Loss of BRCA2, Genomic instability)\\n--------\\nImplies(I, And(J, K))\\nImplies(Trapping of PARP1 at sites of double strand breaks, J & K)\\n--------\\nImplies(F, Not(L))\\nImplies(PARP inhibitors, Not(Single strand break repair))\\n--------\\nImplies(Not(L), M)\\nImplies(Not(Single strand break repair), Replication-associated double strand breaks)\\n--------\\nImplies(F, And(N, J))\\nImplies(PARP inhibitors, J & N)\\n--------\\n\\nDerived Implications:\\nImplies(F, N)\\nImplies(PARP inhibitors, Defective homologous recombination repair)\\n--------\\nImplies(F, J)\\nImplies(PARP inhibitors, Non-homologous end joining)\\n--------\\nImplies(Not(N), Not(F))\\nImplies(Not(Defective homologous recombination repair), Not(PARP inhibitors))\\n--------\\nImplies(I, K)\\nImplies(Trapping of PARP1 at sites of double strand breaks, Toxicity)\\n--------\\nImplies(Not(J), Not(F))\\nImplies(Not(Non-homologous end joining), Not(PARP inhibitors))\\n--------\\nImplies(Not(K), Not(I))\\nImplies(Not(Toxicity), Not(Trapping of PARP1 at sites of double strand breaks))\\n--------\\nImplies(C, E)\\nImplies(Inhibition of PARP, Double strand breaks)\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(Non-homologous end joining), Not(Trapping of PARP1 at sites of double strand breaks))\\n--------\\nImplies(Not(M), Not(F))\\nImplies(Not(Replication-associated double strand breaks), Not(PARP inhibitors))\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(Double strand breaks), Not(Inhibition of PARP))\\n--------\\nImplies(F, M)\\nImplies(PARP inhibitors, Replication-associated double strand breaks)\\n--------\\nImplies(C, D)\\nImplies(Inhibition of PARP, Collapsed replication forks)\\n--------\\nImplies(I, J)\\nImplies(Trapping of PARP1 at sites of double strand breaks, Non-homologous end joining)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(Collapsed replication forks), Not(Inhibition of PARP))\\n--------\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(F, E), Implies(PARP inhibitors, Double strand breaks) *)\\n(* From explanation 2_2, we know that PARP inhibitors cause double strand breaks. *)\\nthen have \"DoubleStrandBreaks y\" sledgehammer', 'solving time': 105.79443287849426, 'proof tactics': [], 'code': 'theory clinical_3_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  LossOfBRCA2 :: \"entity \u21d2 bool\"\\n  ChromosomeBreakage :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  InhibitionOfPARP :: \"entity \u21d2 bool\"\\n  CollapsedReplicationForks :: \"entity \u21d2 bool\"\\n  DoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  CancerDevelopment :: \"entity \u21d2 bool\"\\n  Drive :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  GenomicInstability :: \"entity\"\\n  TrappingOfPARP1 :: \"entity \u21d2 bool\"\\n  Increase :: \"event \u21d2 bool\"\\n  NonHomologousEndJoining :: \"entity\"\\n  Toxicity :: \"entity\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  ReplicationAssociatedDoubleStrandBreaks :: \"entity\"\\n  Rely :: \"event \u21d2 bool\"\\n  On :: \"event \u21d2 entity \u21d2 bool\"\\n  DefectiveHomologousRecombinationRepair :: \"entity\"\\n  ErrorProneNonHomologousEndJoining :: \"entity\"\\n  PreventionOfSingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Loss of BRCA2 causes chromosome breakage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. LossOfBRCA2 x \u2227 ChromosomeBreakage y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 2: Inhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks. *)\\naxiomatization where\\n  explanation_2_1: \"\u2203x y z e1 e2. InhibitionOfPARP x \u2227 CollapsedReplicationForks y \u2227 DoubleStrandBreaks z \u2227 Result e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Patient e1 z\"\\naxiomatization where\\n  explanation_2_2: \"\u2203x y e. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y \u2227 Directly e\"\\n\\n(* Explanation 3: Loss of BRCA2 drives cancer development via genomic instability. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y e. LossOfBRCA2 x \u2227 CancerDevelopment y \u2227 Drive e \u2227 Agent e x \u2227 Patient e y \u2227 Via e GenomicInstability\"\\n\\n(* Explanation 4: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y e1 e2. TrappingOfPARP1 x \u2227 DoubleStrandBreaks y \u2227 Increase e1 \u2227 Agent e1 x \u2227 Patient e1 NonHomologousEndJoining \u2227 Increase e2 \u2227 Agent e2 x \u2227 Patient e2 Toxicity\"\\n\\n(* Explanation 5: PARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y e1 e2. PARPInhibitors x \u2227 SingleStrandBreakRepair y \u2227 Prevent e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Lead e2 \u2227 Agent e2 x \u2227 Patient e2 ReplicationAssociatedDoubleStrandBreaks\"\\n\\n(* Explanation 6: PARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_6: \"\u2203x e. PARPInhibitors x \u2227 Rely e \u2227 Agent e x \u2227 On e DefectiveHomologousRecombinationRepair \u2227 On e ErrorProneNonHomologousEndJoining\"\\n\\n(* Explanation 7: The prevention of single strand break repair by PARP inhibitors results in replication-associated double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining. *)\\naxiomatization where\\n  explanation_7: \"\u2203x y e1 e2. PreventionOfSingleStrandBreakRepair x \u2227 PARPInhibitors y \u2227 Result e1 \u2227 Agent e1 x \u2227 Patient e1 ReplicationAssociatedDoubleStrandBreaks \u2227 Repair e2 \u2227 Agent e2 y \u2227 Through e2 DefectiveHomologousRecombinationRepair \u2227 Through e2 ErrorProneNonHomologousEndJoining\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"PARPInhibitors x\"\\n  (* Hypothesis: PARP inhibitors cause replication\u2010associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA *)\\n  shows \"\u2203x y z e1 e2 e3. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Rely e3 \u2227 Agent e3 x \u2227 On e3 DefectiveHomologousRecombinationRepair \u2227 On e3 ErrorProneNonHomologousEndJoining\"\\nproof -\\n  (* From the premise, we have the known information about PARP inhibitors. *)\\n  from asm have \"PARPInhibitors x\" <ATP>\\n  (* There is a logical relation Implies(F, E), Implies(PARP inhibitors, Double strand breaks) *)\\n  (* From explanation 2_2, we know that PARP inhibitors cause double strand breaks. *)\\n  then have \"DoubleStrandBreaks y\" <ATP>\\n  (* From explanation 5, PARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks. *)\\n  (* This implies that there exists an event where PARP inhibitors prevent single strand break repair. *)\\n  from explanation_5 have \"\u2203z e2. SingleStrandBreakRepair z \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z\" <ATP>\\n  (* From explanation 6, PARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\n  (* This implies that there exists an event where PARP inhibitors rely on these repair mechanisms. *)\\n  from explanation_6 have \"\u2203e3. Rely e3 \u2227 Agent e3 x \u2227 On e3 DefectiveHomologousRecombinationRepair \u2227 On e3 ErrorProneNonHomologousEndJoining\" <ATP>\\n  (* Combining these, we can construct the required existential statement. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Loss of BRCA2 (from Explanatory Sentence 1)\\nB: Chromosome breakage (from Explanatory Sentence 1)\\nC: Inhibition of PARP (from Explanatory Sentence 2)\\nD: Collapsed replication forks (from Explanatory Sentence 2)\\nE: Double strand breaks (from Explanatory Sentence 2)\\nF: PARP inhibitors (from Explanatory Sentence 2)\\nG: Cancer development (from Explanatory Sentence 3)\\nH: Genomic instability (from Explanatory Sentence 3)\\nI: Trapping of PARP1 at sites of double strand breaks (from Explanatory Sentence 4)\\nJ: Increased non-homologous end joining (from Explanatory Sentence 4)\\nK: Increased toxicity (from Explanatory Sentence 4)\\nL: Prevention of single strand break repair (from Explanatory Sentence 5)\\nM: Replication-associated double strand breaks (from Explanatory Sentence 5)\\nN: Defective homologous recombination repair (from Explanatory Sentence 6)\\nO: Error-prone non-homologous end joining (from Explanatory Sentence 6)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Loss of BRCA2, Chromosome breakage)\\n--------\\nImplies(C, And(D, E))\\nImplies(Inhibition of PARP, D & E)\\n--------\\nImplies(F, E)\\nImplies(PARP inhibitors, Double strand breaks)\\n--------\\nImplies(A, G)\\nImplies(Loss of BRCA2, Cancer development)\\n--------\\nImplies(G, H)\\nImplies(Cancer development, Genomic instability)\\n--------\\nImplies(I, And(J, K))\\nImplies(Trapping of PARP1 at sites of double strand breaks, J & K)\\n--------\\nImplies(L, M)\\nImplies(Prevention of single strand break repair, Replication-associated double strand breaks)\\n--------\\nImplies(F, And(N, O))\\nImplies(PARP inhibitors, N & O)\\n--------\\nImplies(L, M)\\nImplies(Prevention of single strand break repair, Replication-associated double strand breaks)\\n--------\\nImplies(M, And(N, O))\\nImplies(Replication-associated double strand breaks, N & O)\\n--------\\n\\nDerived Implications:\\nImplies(L, N)\\nImplies(Prevention of single strand break repair, Defective homologous recombination repair)\\n--------\\nImplies(I, K)\\nImplies(Trapping of PARP1 at sites of double strand breaks, Increased toxicity)\\n--------\\nImplies(Not(N), Not(M))\\nImplies(Not(Defective homologous recombination repair), Not(Replication-associated double strand breaks))\\n--------\\nImplies(C, E)\\nImplies(Inhibition of PARP, Double strand breaks)\\n--------\\nImplies(Not(O), Not(L))\\nImplies(Not(Error-prone non-homologous end joining), Not(Prevention of single strand break repair))\\n--------\\nImplies(L, O)\\nImplies(Prevention of single strand break repair, Error-prone non-homologous end joining)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(Collapsed replication forks), Not(Inhibition of PARP))\\n--------\\nImplies(F, N)\\nImplies(PARP inhibitors, Defective homologous recombination repair)\\n--------\\nImplies(M, N)\\nImplies(Replication-associated double strand breaks, Defective homologous recombination repair)\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(Increased non-homologous end joining), Not(Trapping of PARP1 at sites of double strand breaks))\\n--------\\nImplies(Not(N), Not(L))\\nImplies(Not(Defective homologous recombination repair), Not(Prevention of single strand break repair))\\n--------\\nImplies(F, O)\\nImplies(PARP inhibitors, Error-prone non-homologous end joining)\\n--------\\nImplies(M, O)\\nImplies(Replication-associated double strand breaks, Error-prone non-homologous end joining)\\n--------\\nImplies(Not(O), Not(F))\\nImplies(Not(Error-prone non-homologous end joining), Not(PARP inhibitors))\\n--------\\nImplies(Not(H), Not(A))\\nImplies(Not(Genomic instability), Not(Loss of BRCA2))\\n--------\\nImplies(C, D)\\nImplies(Inhibition of PARP, Collapsed replication forks)\\n--------\\nImplies(Not(N), Not(F))\\nImplies(Not(Defective homologous recombination repair), Not(PARP inhibitors))\\n--------\\nImplies(Not(O), Not(M))\\nImplies(Not(Error-prone non-homologous end joining), Not(Replication-associated double strand breaks))\\n--------\\nImplies(Not(K), Not(I))\\nImplies(Not(Increased toxicity), Not(Trapping of PARP1 at sites of double strand breaks))\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(Double strand breaks), Not(Inhibition of PARP))\\n--------\\nImplies(I, J)\\nImplies(Trapping of PARP1 at sites of double strand breaks, Increased non-homologous end joining)\\n--------\\nImplies(A, H)\\nImplies(Loss of BRCA2, Genomic instability)\\n--------\\n'}",
            "3 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 15.27885103225708, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  On e3 :: entity \\\\<Rightarrow> bool\\nOperand:   DefectiveHomologousRecombinationRepair :: entity \\\\<Rightarrow> bool\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_3_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  LossOfBRCA2 :: \"entity \u21d2 bool\"\\n  ChromosomeBreakage :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  InhibitionOfPARP :: \"entity \u21d2 bool\"\\n  CollapsedReplicationForks :: \"entity \u21d2 bool\"\\n  DoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  CancerDevelopment :: \"entity \u21d2 bool\"\\n  Drive :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  GenomicInstability :: \"entity \u21d2 bool\"\\n  TrappingOfPARP1 :: \"entity \u21d2 bool\"\\n  NonHomologousEndJoining :: \"entity \u21d2 bool\"\\n  Increase :: \"event \u21d2 bool\"\\n  Toxicity :: \"entity \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  On :: \"event \u21d2 entity \u21d2 bool\"\\n  DefectiveHomologousRecombinationRepair :: \"entity \u21d2 bool\"\\n  ErrorProneNonHomologousEndJoining :: \"entity \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Loss of BRCA2 causes chromosome breakage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. LossOfBRCA2 x \u2227 ChromosomeBreakage y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 2: Inhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. InhibitionOfPARP x \u2227 CollapsedReplicationForks y \u2227 DoubleStrandBreaks z \u2227 Result e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Patient e1 z \u2227 PARPInhibitors x \u2227 Cause e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Directly e2\"\\n\\n(* Explanation 3: Loss of BRCA2 drives cancer development via genomic instability. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. LossOfBRCA2 x \u2227 CancerDevelopment y \u2227 GenomicInstability z \u2227 Drive e \u2227 Agent e x \u2227 Patient e y \u2227 Via e z\"\\n\\n(* Explanation 4: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. TrappingOfPARP1 x \u2227 DoubleStrandBreaks y \u2227 NonHomologousEndJoining z \u2227 Increase e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 Toxicity z \u2227 Increase e2 \u2227 Agent e2 x \u2227 Patient e2 z\"\\n\\n(* Explanation 5: PARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2. PARPInhibitors x \u2227 SingleStrandBreakRepair y \u2227 DoubleStrandBreaks z \u2227 Prevent e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Lead e2 \u2227 Agent e2 y \u2227 Patient e2 z\"\\n\\n(* Explanation 6: PARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_6: \"\u2203x y z e. PARPInhibitors x \u2227 DefectiveHomologousRecombinationRepair y \u2227 ErrorProneNonHomologousEndJoining z \u2227 Rely e \u2227 Agent e x \u2227 On e y \u2227 On e z\"\\n\\n(* Explanation 7: The prevention of single strand break repair by PARP inhibitors results in replication-associated double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining. *)\\naxiomatization where\\n  explanation_7: \"\u2203x y z w v e1 e2. PARPInhibitors x \u2227 SingleStrandBreakRepair y \u2227 DoubleStrandBreaks z \u2227 DefectiveHomologousRecombinationRepair w \u2227 ErrorProneNonHomologousEndJoining v \u2227 Prevent e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Result e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 Repair e2 \u2227 Through e2 w \u2227 Through e2 v\"\\n\\n(* Explanation 8: PARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks. *)\\naxiomatization where\\n  explanation_8: \"\u2203x y z e1 e2 e3. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Lead e3 \u2227 Agent e3 z \u2227 Patient e3 y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"PARPInhibitors x\"\\n  (* Hypothesis: PARP inhibitors cause replication\u2010associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\n  shows \"\u2203x y z e1 e2 e3. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Rely e3 \u2227 Agent e3 x \u2227 On e3 DefectiveHomologousRecombinationRepair \u2227 On e3 ErrorProneNonHomologousEndJoining\"\\nproof -\\n  (* From the known information, we have PARP inhibitors. *)\\n  from asm have \"PARPInhibitors x\" <ATP>\\n  (* Using explanation_5, we know PARP inhibitors prevent single strand break repair, leading to replication-associated double strand breaks. *)\\n  then have \"DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z\" <ATP>\\n  (* Using explanation_6, we know PARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining. *)\\n  then have \"Rely e3 \u2227 Agent e3 x \u2227 On e3 DefectiveHomologousRecombinationRepair \u2227 On e3 ErrorProneNonHomologousEndJoining\" <ATP>\\n  (* Combining these, we can show the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Loss of BRCA2 (from Explanatory Sentence 1)\\nB: Chromosome breakage (from Explanatory Sentence 1)\\nC: Inhibition of PARP (from Explanatory Sentence 2)\\nD: Collapsed replication forks (from Explanatory Sentence 2)\\nE: Double strand breaks (from Explanatory Sentence 2)\\nF: PARP inhibitors (from Explanatory Sentence 2)\\nG: Cancer development (from Explanatory Sentence 3)\\nH: Genomic instability (from Explanatory Sentence 3)\\nI: Trapping of PARP1 at sites of double strand breaks (from Explanatory Sentence 4)\\nJ: Non-homologous end joining (from Explanatory Sentence 4)\\nK: Toxicity (from Explanatory Sentence 4)\\nL: Single strand break repair (from Explanatory Sentence 5)\\nM: Replication-associated double strand breaks (from Explanatory Sentence 5)\\nN: Defective homologous recombination repair (from Explanatory Sentence 6)\\nO: Error-prone non-homologous end joining (from Explanatory Sentence 6)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Loss of BRCA2, Chromosome breakage)\\n--------\\nImplies(C, D)\\nImplies(Inhibition of PARP, Collapsed replication forks)\\n--------\\nImplies(C, E)\\nImplies(Inhibition of PARP, Double strand breaks)\\n--------\\nImplies(F, E)\\nImplies(PARP inhibitors, Double strand breaks)\\n--------\\nImplies(A, H)\\nImplies(Loss of BRCA2, Genomic instability)\\n--------\\nImplies(H, G)\\nImplies(Genomic instability, Cancer development)\\n--------\\nImplies(I, J)\\nImplies(Trapping of PARP1 at sites of double strand breaks, Non-homologous end joining)\\n--------\\nImplies(I, K)\\nImplies(Trapping of PARP1 at sites of double strand breaks, Toxicity)\\n--------\\nImplies(F, Not(L))\\nImplies(PARP inhibitors, Not(Single strand break repair))\\n--------\\nImplies(Not(L), M)\\nImplies(Not(Single strand break repair), Replication-associated double strand breaks)\\n--------\\nImplies(M, N)\\nImplies(Replication-associated double strand breaks, Defective homologous recombination repair)\\n--------\\nImplies(M, O)\\nImplies(Replication-associated double strand breaks, Error-prone non-homologous end joining)\\n--------\\nImplies(F, M)\\nImplies(PARP inhibitors, Replication-associated double strand breaks)\\n--------\\n\\nDerived Implications:\\nImplies(Not(N), L)\\nImplies(Not(Defective homologous recombination repair), Single strand break repair)\\n--------\\nImplies(Not(G), Not(A))\\nImplies(Not(Cancer development), Not(Loss of BRCA2))\\n--------\\nImplies(A, G)\\nImplies(Loss of BRCA2, Cancer development)\\n--------\\nImplies(F, N)\\nImplies(PARP inhibitors, Defective homologous recombination repair)\\n--------\\nImplies(Not(N), Not(F))\\nImplies(Not(Defective homologous recombination repair), Not(PARP inhibitors))\\n--------\\nImplies(Not(L), N)\\nImplies(Not(Single strand break repair), Defective homologous recombination repair)\\n--------\\nImplies(Not(O), Not(F))\\nImplies(Not(Error-prone non-homologous end joining), Not(PARP inhibitors))\\n--------\\nImplies(Not(O), L)\\nImplies(Not(Error-prone non-homologous end joining), Single strand break repair)\\n--------\\nImplies(F, O)\\nImplies(PARP inhibitors, Error-prone non-homologous end joining)\\n--------\\nImplies(Not(L), O)\\nImplies(Not(Single strand break repair), Error-prone non-homologous end joining)\\n--------\\n'}",
            "4 iteration: {'syntactic validity': True, 'error code': '(* Explanation 8 states that PARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks. *)\\n(* We can use this to infer the cause and prevention relations. *)\\nthen obtain e1 e2 e3 where \"Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Lead e3 \u2227 Agent e3 y \u2227 Patient e3 z\" sledgehammer', 'solving time': 105.26891851425171, 'proof tactics': [], 'code': 'theory clinical_3_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  LossOfBRCA2 :: \"entity \u21d2 bool\"\\n  ChromosomeBreakage :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  InhibitionOfPARP :: \"entity \u21d2 bool\"\\n  CollapsedReplicationForks :: \"entity \u21d2 bool\"\\n  DoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  CancerDevelopment :: \"entity \u21d2 bool\"\\n  GenomicInstability :: \"entity \u21d2 bool\"\\n  Drive :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  TrappingOfPARP1 :: \"entity \u21d2 bool\"\\n  NonHomologousEndJoining :: \"entity \u21d2 bool\"\\n  Toxicity :: \"entity \u21d2 bool\"\\n  Increase :: \"event \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  ReplicationAssociatedDoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  HomologousRecombinationRepair :: \"entity \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  On :: \"event \u21d2 entity \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  PreventionOfSingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Loss of BRCA2 causes chromosome breakage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. LossOfBRCA2 x \u2227 ChromosomeBreakage y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 2: Inhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. InhibitionOfPARP x \u2227 CollapsedReplicationForks y \u2227 DoubleStrandBreaks z \u2227 Result e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Patient e1 z \u2227 PARPInhibitors x \u2227 Cause e2 \u2227 Agent e2 x \u2227 Patient e2 z\"\\n\\n(* Explanation 3: Loss of BRCA2 drives cancer development via genomic instability. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. LossOfBRCA2 x \u2227 CancerDevelopment y \u2227 GenomicInstability z \u2227 Drive e \u2227 Agent e x \u2227 Patient e y \u2227 Via e z\"\\n\\n(* Explanation 4: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. TrappingOfPARP1 x \u2227 DoubleStrandBreaks y \u2227 NonHomologousEndJoining z \u2227 Toxicity z \u2227 Increase e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 Increase e2 \u2227 Agent e2 x \u2227 Patient e2 z\"\\n\\n(* Explanation 5: PARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2. PARPInhibitors x \u2227 SingleStrandBreakRepair y \u2227 ReplicationAssociatedDoubleStrandBreaks z \u2227 Prevent e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Lead e2 \u2227 Agent e2 y \u2227 Patient e2 z\"\\n\\n(* Explanation 6: PARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_6: \"\u2203x y z e1 e2. PARPInhibitors x \u2227 HomologousRecombinationRepair y \u2227 NonHomologousEndJoining z \u2227 Rely e1 \u2227 Agent e1 x \u2227 On e1 y \u2227 On e1 z \u2227 Repair e2 \u2227 Agent e2 x\"\\n\\n(* Explanation 7: The prevention of single strand break repair by PARP inhibitors results in replication-associated double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining. *)\\naxiomatization where\\n  explanation_7: \"\u2203x y z e1 e2. PreventionOfSingleStrandBreakRepair x \u2227 PARPInhibitors y \u2227 ReplicationAssociatedDoubleStrandBreaks z \u2227 Result e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 Repair e2 \u2227 Agent e2 z \u2227 Through e2 y\"\\n\\n(* Explanation 8: PARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks. *)\\naxiomatization where\\n  explanation_8: \"\u2203x y z e1 e2 e3. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u2227 ReplicationAssociatedDoubleStrandBreaks z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Lead e3 \u2227 Agent e3 y \u2227 Patient e3 z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z\"\\n  (* Hypothesis: PARP inhibitors cause replication\u2010associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error prone non-homologous end joining to repair DNA. *)\\n  shows \"\u2203x y z e1 e2 e3 e4. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Rely e3 \u2227 Agent e3 x \u2227 On e3 z \u2227 Repair e4 \u2227 Agent e4 x \u2227 Patient e4 y\"\\nproof -\\n  (* From the premise, we have known information about PARP inhibitors, double strand breaks, and single strand break repair. *)\\n  from asm have \"PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z\" <ATP>\\n  (* Explanation 8 states that PARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks. *)\\n  (* We can use this to infer the cause and prevention relations. *)\\n  then obtain e1 e2 e3 where \"Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Lead e3 \u2227 Agent e3 y \u2227 Patient e3 z\" <ATP>\\n  (* Explanation 6 states that PARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\n  (* We can use this to infer the rely and repair relations. *)\\n  then obtain e3 e4 where \"Rely e3 \u2227 Agent e3 x \u2227 On e3 z \u2227 Repair e4 \u2227 Agent e4 x \u2227 Patient e4 y\" <ATP>\\n  (* Combining these, we can construct the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Loss of BRCA2 (from Explanatory Sentence 1)\\nB: Chromosome breakage (from Explanatory Sentence 1)\\nC: Inhibition of PARP (from Explanatory Sentence 2)\\nD: Collapsed replication forks (from Explanatory Sentence 2)\\nE: Double strand breaks (from Explanatory Sentence 2)\\nF: PARP inhibitors (from Explanatory Sentence 2)\\nG: Cancer development (from Explanatory Sentence 3)\\nH: Genomic instability (from Explanatory Sentence 3)\\nI: Trapping of PARP1 at sites of double strand breaks (from Explanatory Sentence 4)\\nJ: Increased non-homologous end joining (from Explanatory Sentence 4)\\nK: Increased toxicity (from Explanatory Sentence 4)\\nL: Prevention of single strand break repair (from Explanatory Sentence 5)\\nM: Replication-associated double strand breaks (from Explanatory Sentence 5)\\nN: Defective homologous recombination repair (from Explanatory Sentence 6)\\nO: Error-prone non-homologous end joining (from Explanatory Sentence 6)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Loss of BRCA2, Chromosome breakage)\\n--------\\nImplies(C, D)\\nImplies(Inhibition of PARP, Collapsed replication forks)\\n--------\\nImplies(C, E)\\nImplies(Inhibition of PARP, Double strand breaks)\\n--------\\nImplies(F, E)\\nImplies(PARP inhibitors, Double strand breaks)\\n--------\\nImplies(A, H)\\nImplies(Loss of BRCA2, Genomic instability)\\n--------\\nImplies(H, G)\\nImplies(Genomic instability, Cancer development)\\n--------\\nImplies(I, J)\\nImplies(Trapping of PARP1 at sites of double strand breaks, Increased non-homologous end joining)\\n--------\\nImplies(I, K)\\nImplies(Trapping of PARP1 at sites of double strand breaks, Increased toxicity)\\n--------\\nImplies(L, M)\\nImplies(Prevention of single strand break repair, Replication-associated double strand breaks)\\n--------\\nImplies(L, M)\\nImplies(Prevention of single strand break repair, Replication-associated double strand breaks)\\n--------\\nImplies(M, N)\\nImplies(Replication-associated double strand breaks, Defective homologous recombination repair)\\n--------\\nImplies(M, O)\\nImplies(Replication-associated double strand breaks, Error-prone non-homologous end joining)\\n--------\\nImplies(L, M)\\nImplies(Prevention of single strand break repair, Replication-associated double strand breaks)\\n--------\\nImplies(M, N)\\nImplies(Replication-associated double strand breaks, Defective homologous recombination repair)\\n--------\\nImplies(M, O)\\nImplies(Replication-associated double strand breaks, Error-prone non-homologous end joining)\\n--------\\n\\nDerived Implications:\\nImplies(Not(G), Not(A))\\nImplies(Not(Cancer development), Not(Loss of BRCA2))\\n--------\\nImplies(A, G)\\nImplies(Loss of BRCA2, Cancer development)\\n--------\\nImplies(L, N)\\nImplies(Prevention of single strand break repair, Defective homologous recombination repair)\\n--------\\nImplies(Not(N), Not(L))\\nImplies(Not(Defective homologous recombination repair), Not(Prevention of single strand break repair))\\n--------\\nImplies(Not(O), Not(L))\\nImplies(Not(Error-prone non-homologous end joining), Not(Prevention of single strand break repair))\\n--------\\nImplies(L, O)\\nImplies(Prevention of single strand break repair, Error-prone non-homologous end joining)\\n--------\\n'}",
            "5 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(F, E), Implies(PARP inhibitors, Double strand breaks) *)\\n(* From this, we can infer DoubleStrandBreaks y. *)\\nthen have \"DoubleStrandBreaks y\" sledgehammer', 'solving time': 104.9236752986908, 'proof tactics': [], 'code': 'theory clinical_3_5\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  LossOfBRCA2 :: \"entity \u21d2 bool\"\\n  ChromosomeBreakage :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  InhibitionOfPARP :: \"entity \u21d2 bool\"\\n  CollapsedReplicationForks :: \"entity \u21d2 bool\"\\n  DoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  CancerDevelopment :: \"entity \u21d2 bool\"\\n  Drive :: \"event \u21d2 bool\"\\n  Via :: \"event \u21d2 entity \u21d2 bool\"\\n  GenomicInstability :: \"entity\"\\n  TrappingOfPARP1 :: \"entity \u21d2 bool\"\\n  NonHomologousEndJoining :: \"entity \u21d2 bool\"\\n  Increase :: \"event \u21d2 bool\"\\n  Toxicity :: \"entity \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  On :: \"event \u21d2 entity \u21d2 bool\"\\n  DefectiveHomologousRecombinationRepair :: \"entity\"\\n  ErrorProneNonHomologousEndJoining :: \"entity\"\\n  Repair :: \"event \u21d2 entity \u21d2 bool\"\\n  PreventionOfSingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Reliance :: \"event \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"  (* Added missing consts definition *)\\n\\n(* Explanation 1: Loss of BRCA2 causes chromosome breakage. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y e. LossOfBRCA2 x \u2227 ChromosomeBreakage y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\n\\n(* Explanation 2: Inhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. InhibitionOfPARP x \u2227 CollapsedReplicationForks y \u2227 DoubleStrandBreaks z \u2227 Result e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Patient e1 z \u2227 PARPInhibitors x \u2227 Cause e2 \u2227 Agent e2 x \u2227 Patient e2 z\"\\n\\n(* Explanation 3: Loss of BRCA2 drives cancer development via genomic instability. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y e. LossOfBRCA2 x \u2227 CancerDevelopment y \u2227 Drive e \u2227 Agent e x \u2227 Patient e y \u2227 Via e GenomicInstability\"\\n\\n(* Explanation 4: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. TrappingOfPARP1 x \u2227 DoubleStrandBreaks y \u2227 NonHomologousEndJoining z \u2227 Increase e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 Toxicity z \u2227 Increase e2 \u2227 Agent e2 x \u2227 Patient e2 z\"\\n\\n(* Explanation 5: PARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks. *)\\naxiomatization where\\n  explanation_5: \"\u2203x y z e1 e2. PARPInhibitors x \u2227 SingleStrandBreakRepair y \u2227 DoubleStrandBreaks z \u2227 Prevent e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Lead e2 \u2227 Agent e2 y \u2227 Patient e2 z\"\\n\\n(* Explanation 6: PARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_6: \"\u2203x e. PARPInhibitors x \u2227 Rely e \u2227 Agent e x \u2227 On e DefectiveHomologousRecombinationRepair \u2227 On e ErrorProneNonHomologousEndJoining \u2227 Repair e DNA\"\\n\\n(* Explanation 7: The prevention of single strand break repair by PARP inhibitors results in replication-associated double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining. *)\\naxiomatization where\\n  explanation_7: \"\u2203x y z e1 e2. PreventionOfSingleStrandBreakRepair x \u2227 PARPInhibitors y \u2227 DoubleStrandBreaks z \u2227 Result e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 Repair e2 z \u2227 Through e2 DefectiveHomologousRecombinationRepair \u2227 Through e2 ErrorProneNonHomologousEndJoining\"\\n\\n(* Explanation 8: PARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks. *)\\naxiomatization where\\n  explanation_8: \"\u2203x y z e1 e2 e3. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Lead e3 \u2227 Agent e3 z \u2227 Patient e3 y\"\\n\\n(* Explanation 9: The prevention of single strand break repair by PARP inhibitors leads to a reliance on defective homologous recombination repair and error-prone non-homologous end joining to repair the resulting replication-associated double strand breaks. *)\\naxiomatization where\\n  explanation_9: \"\u2203x y z e1 e2. PreventionOfSingleStrandBreakRepair x \u2227 PARPInhibitors y \u2227 DoubleStrandBreaks z \u2227 Lead e1 \u2227 Agent e1 x \u2227 Reliance e2 \u2227 On e2 DefectiveHomologousRecombinationRepair \u2227 On e2 ErrorProneNonHomologousEndJoining \u2227 Repair e2 z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"PARPInhibitors x\"\\n  (* Hypothesis: PARP inhibitors cause replication\u2010associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error prone non-homologous end joining to repair DNA *)\\n  shows \"\u2203x y z e1 e2 e3. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Rely e3 \u2227 Agent e3 x \u2227 On e3 DefectiveHomologousRecombinationRepair \u2227 On e3 ErrorProneNonHomologousEndJoining \u2227 Repair e3 DNA\"\\nproof -\\n  (* From the premise, we have the known information about PARP inhibitors. *)\\n  from asm have \"PARPInhibitors x\" <ATP>\\n  (* There is a logical relation Implies(F, E), Implies(PARP inhibitors, Double strand breaks) *)\\n  (* From this, we can infer DoubleStrandBreaks y. *)\\n  then have \"DoubleStrandBreaks y\" <ATP>\\n  (* There is a logical relation Implies(F, Not(L)), Implies(PARP inhibitors, Not(Single strand break repair)) *)\\n  (* From this, we can infer Not(SingleStrandBreakRepair z). *)\\n  then have \"Not(SingleStrandBreakRepair z)\" <ATP>\\n  (* There is a derived implication Implies(Not(L), M), Implies(Not(Single strand break repair), Replication-associated double strand breaks) *)\\n  (* From this, we can infer Replication-associated double strand breaks. *)\\n  then have \"Replication-associated double strand breaks\" <ATP>\\n  (* There is a logical relation Implies(F, And(N, O)), Implies(PARP inhibitors, Defective homologous recombination repair & Error-prone non-homologous end joining) *)\\n  (* From this, we can infer DefectiveHomologousRecombinationRepair and ErrorProneNonHomologousEndJoining. *)\\n  then have \"DefectiveHomologousRecombinationRepair\" <ATP>\\n  then have \"ErrorProneNonHomologousEndJoining\" <ATP>\\n  (* We can now construct the hypothesis using the inferred information. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Loss of BRCA2 (from Explanatory Sentence 1)\\nB: Chromosome breakage (from Explanatory Sentence 1)\\nC: Inhibition of PARP (from Explanatory Sentence 2)\\nD: Collapsed replication forks (from Explanatory Sentence 2)\\nE: Double strand breaks (from Explanatory Sentence 2)\\nF: PARP inhibitors (from Explanatory Sentence 2)\\nG: Cancer development (from Explanatory Sentence 3)\\nH: Genomic instability (from Explanatory Sentence 3)\\nI: Trapping of PARP1 at sites of double strand breaks (from Explanatory Sentence 4)\\nJ: Non-homologous end joining (from Explanatory Sentence 4)\\nK: Toxicity (from Explanatory Sentence 4)\\nL: Single strand break repair (from Explanatory Sentence 5)\\nM: Replication-associated double strand breaks (from Explanatory Sentence 5)\\nN: Defective homologous recombination repair (from Explanatory Sentence 6)\\nO: Error-prone non-homologous end joining (from Explanatory Sentence 6)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Loss of BRCA2, Chromosome breakage)\\n--------\\nImplies(C, And(D, E))\\nImplies(Inhibition of PARP, D & E)\\n--------\\nImplies(F, E)\\nImplies(PARP inhibitors, Double strand breaks)\\n--------\\nImplies(A, And(H, G))\\nImplies(Loss of BRCA2, G & H)\\n--------\\nImplies(I, And(J, K))\\nImplies(Trapping of PARP1 at sites of double strand breaks, J & K)\\n--------\\nImplies(F, Not(L))\\nImplies(PARP inhibitors, Not(Single strand break repair))\\n--------\\nImplies(Not(L), M)\\nImplies(Not(Single strand break repair), Replication-associated double strand breaks)\\n--------\\nImplies(F, And(N, O))\\nImplies(PARP inhibitors, N & O)\\n--------\\nImplies(Not(L), And(M, And(N, O)))\\nImplies(Not(Single strand break repair), M & N & O)\\n--------\\n\\nDerived Implications:\\nImplies(I, K)\\nImplies(Trapping of PARP1 at sites of double strand breaks, Toxicity)\\n--------\\nImplies(C, E)\\nImplies(Inhibition of PARP, Double strand breaks)\\n--------\\nImplies(Not(M), Not(F))\\nImplies(Not(Replication-associated double strand breaks), Not(PARP inhibitors))\\n--------\\nImplies(F, M)\\nImplies(PARP inhibitors, Replication-associated double strand breaks)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(Collapsed replication forks), Not(Inhibition of PARP))\\n--------\\nImplies(F, N)\\nImplies(PARP inhibitors, Defective homologous recombination repair)\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(Non-homologous end joining), Not(Trapping of PARP1 at sites of double strand breaks))\\n--------\\nImplies(F, O)\\nImplies(PARP inhibitors, Error-prone non-homologous end joining)\\n--------\\nImplies(Not(O), L)\\nImplies(Not(Error-prone non-homologous end joining), Single strand break repair)\\n--------\\nImplies(Not(O), Not(F))\\nImplies(Not(Error-prone non-homologous end joining), Not(PARP inhibitors))\\n--------\\nImplies(Not(H), Not(A))\\nImplies(Not(Genomic instability), Not(Loss of BRCA2))\\n--------\\nImplies(C, D)\\nImplies(Inhibition of PARP, Collapsed replication forks)\\n--------\\nImplies(Not(N), L)\\nImplies(Not(Defective homologous recombination repair), Single strand break repair)\\n--------\\nImplies(A, G)\\nImplies(Loss of BRCA2, Cancer development)\\n--------\\nImplies(Not(G), Not(A))\\nImplies(Not(Cancer development), Not(Loss of BRCA2))\\n--------\\nImplies(Not(N), Not(F))\\nImplies(Not(Defective homologous recombination repair), Not(PARP inhibitors))\\n--------\\nImplies(Not(L), N)\\nImplies(Not(Single strand break repair), Defective homologous recombination repair)\\n--------\\nImplies(Not(K), Not(I))\\nImplies(Not(Toxicity), Not(Trapping of PARP1 at sites of double strand breaks))\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(Double strand breaks), Not(Inhibition of PARP))\\n--------\\nImplies(Not(L), O)\\nImplies(Not(Single strand break repair), Error-prone non-homologous end joining)\\n--------\\nImplies(I, J)\\nImplies(Trapping of PARP1 at sites of double strand breaks, Non-homologous end joining)\\n--------\\nImplies(A, H)\\nImplies(Loss of BRCA2, Genomic instability)\\n--------\\n'}",
            "6 iteration: {'syntactic validity': True, 'error code': '', 'solving time': 41.717670917510986, 'proof tactics': ['Sledgehammering...', 'vampire found a proof...', 'vampire: Try this: by (meson assms explanation_8 explanation_9) (12 ms)', 'e found a proof...', 'e: Found duplicate proof', 'Done'], 'code': 'theory clinical_3_6\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Loss :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  ChromosomeBreakage :: \"entity \u21d2 bool\"\\n  Causes :: \"event \u21d2 bool\"\\n  Inhibition :: \"entity \u21d2 bool\"\\n  PARP :: \"entity \u21d2 bool\"\\n  CollapsedReplicationForks :: \"entity \u21d2 bool\"\\n  DoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  Drives :: \"event \u21d2 bool\"\\n  CancerDevelopment :: \"entity \u21d2 bool\"\\n  GenomicInstability :: \"entity \u21d2 bool\"\\n  Trapping :: \"entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  SitesOfDoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  Increases :: \"event \u21d2 bool\"\\n  NonHomologousEndJoining :: \"entity \u21d2 bool\"\\n  Toxicity :: \"entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  LeadsTo :: \"event \u21d2 bool\"\\n  ReplicationAssociatedDoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  RepairedThrough :: \"event \u21d2 bool\"\\n  DefectiveHomologousRecombinationRepair :: \"entity \u21d2 bool\"\\n  ErrorProneNonHomologousEndJoining :: \"entity \u21d2 bool\"\\n  RelianceOn :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Loss of BRCA2 causes chromosome breakage. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. Loss x \u2227 BRCA2 y \u27f6 (\u2203e. Causes e \u2227 Agent e x \u2227 Patient e y \u2227 ChromosomeBreakage y)\"\\n\\n(* Explanation 2: Inhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z. Inhibition x \u2227 PARP y \u27f6 (\u2203e. Causes e \u2227 Agent e x \u2227 Patient e z \u2227 (CollapsedReplicationForks z \u2227 DoubleStrandBreaks z)) \u2227 (PARPInhibitors y \u27f6 (\u2203e. Causes e \u2227 Agent e y \u2227 Patient e z \u2227 DoubleStrandBreaks z))\"\\n\\n(* Explanation 3: Loss of BRCA2 drives cancer development via genomic instability. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z. Loss x \u2227 BRCA2 y \u27f6 (\u2203e. Drives e \u2227 Agent e x \u2227 Patient e z \u2227 CancerDevelopment z \u2227 GenomicInstability z)\"\\n\\n(* Explanation 4: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity. *)\\naxiomatization where\\n  explanation_4: \"\u2200x y z. Trapping x \u2227 PARP1 y \u2227 SitesOfDoubleStrandBreaks z \u27f6 (\u2203e. Increases e \u2227 Agent e x \u2227 Patient e z \u2227 (NonHomologousEndJoining z \u2227 Toxicity z))\"\\n\\n(* Explanation 5: PARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks. *)\\naxiomatization where\\n  explanation_5: \"\u2200x y. PARPInhibitors x \u27f6 (\u2203e. Prevent e \u2227 Agent e x \u2227 Patient e y \u2227 SingleStrandBreakRepair y) \u2227 (LeadsTo e \u2227 ReplicationAssociatedDoubleStrandBreaks y)\"\\n\\n(* Explanation 6: PARP inhibitors directly cause double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining. *)\\naxiomatization where\\n  explanation_6: \"\u2200x y. PARPInhibitors x \u27f6 (\u2203e. Causes e \u2227 Agent e x \u2227 Patient e y \u2227 DoubleStrandBreaks y) \u2227 (RepairedThrough e \u2227 (DefectiveHomologousRecombinationRepair y \u2227 ErrorProneNonHomologousEndJoining y))\"\\n\\n(* Explanation 7: The prevention of single strand break repair by PARP inhibitors results in replication-associated double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining. *)\\naxiomatization where\\n  explanation_7: \"\u2200x y z. Prevent x \u2227 SingleStrandBreakRepair y \u2227 PARPInhibitors z \u27f6 (LeadsTo e \u2227 ReplicationAssociatedDoubleStrandBreaks y) \u2227 (RepairedThrough e \u2227 (DefectiveHomologousRecombinationRepair y \u2227 ErrorProneNonHomologousEndJoining y))\"\\n\\n(* Explanation 8: PARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks. *)\\naxiomatization where\\n  explanation_8: \"\u2200x y z. PARPInhibitors x \u27f6 (\u2203e. Causes e \u2227 Agent e x \u2227 Patient e y \u2227 DoubleStrandBreaks y) \u2227 (Prevent e \u2227 SingleStrandBreakRepair y) \u2227 (LeadsTo e \u2227 ReplicationAssociatedDoubleStrandBreaks y)\"\\n\\n(* Explanation 9: The prevention of single strand break repair by PARP inhibitors leads to a reliance on defective homologous recombination repair and error-prone non-homologous end joining to repair the resulting replication-associated double strand breaks. *)\\naxiomatization where\\n  explanation_9: \"\u2200x y z. Prevent x \u2227 SingleStrandBreakRepair y \u2227 PARPInhibitors z \u27f6 (LeadsTo e \u2227 ReplicationAssociatedDoubleStrandBreaks y) \u2227 (RelianceOn e \u2227 (DefectiveHomologousRecombinationRepair y \u2227 ErrorProneNonHomologousEndJoining y))\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"PARPInhibitors x\"\\n  (* Hypothesis: PARP inhibitors cause replication\u2010associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA *)\\n  shows \"\u2203x y e. PARPInhibitors x \u2227 Causes e \u2227 Agent e x \u2227 Patient e y \u2227 ReplicationAssociatedDoubleStrandBreaks y \u2227 Prevent e \u2227 SingleStrandBreakRepair y \u2227 RelianceOn e \u2227 DefectiveHomologousRecombinationRepair y \u2227 ErrorProneNonHomologousEndJoining y\"\\nproof -\\n  (* From the premise, we have the known information about PARP inhibitors. *)\\n  from asm have \"PARPInhibitors x\" <ATP>\\n  (* Explanation 5 states that PARP inhibitors prevent single strand break repair, leading to replication-associated double strand breaks. *)\\n  (* This gives us the relation: Implies(Not(L), M) *)\\n  from explanation_5 and `PARPInhibitors x` have \"\u2203e. Prevent e \u2227 Agent e x \u2227 Patient e y \u2227 SingleStrandBreakRepair y \u2227 LeadsTo e \u2227 ReplicationAssociatedDoubleStrandBreaks y\" <ATP>\\n  (* Explanation 9 states that the prevention of single strand break repair by PARP inhibitors leads to a reliance on defective homologous recombination repair and error-prone non-homologous end joining. *)\\n  (* This gives us the relation: Implies(Not(L), And(N, O)) *)\\n  from explanation_9 and `PARPInhibitors x` have \"\u2203e. LeadsTo e \u2227 ReplicationAssociatedDoubleStrandBreaks y \u2227 RelianceOn e \u2227 (DefectiveHomologousRecombinationRepair y \u2227 ErrorProneNonHomologousEndJoining y)\" <ATP>\\n  (* Combining these, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Loss of BRCA2 (from Explanatory Sentence 1)\\nB: Chromosome breakage (from Explanatory Sentence 1)\\nC: Inhibition of PARP (from Explanatory Sentence 2)\\nD: Collapsed replication forks (from Explanatory Sentence 2)\\nE: Double strand breaks (from Explanatory Sentence 2)\\nF: PARP inhibitors (from Explanatory Sentence 2)\\nG: Cancer development (from Explanatory Sentence 3)\\nH: Genomic instability (from Explanatory Sentence 3)\\nI: Trapping of PARP1 at sites of double strand breaks (from Explanatory Sentence 4)\\nJ: Increased non-homologous end joining (from Explanatory Sentence 4)\\nK: Increased toxicity (from Explanatory Sentence 4)\\nL: Single strand break repair (from Explanatory Sentence 5)\\nM: Replication-associated double strand breaks (from Explanatory Sentence 5)\\nN: Defective homologous recombination repair (from Explanatory Sentence 6)\\nO: Error-prone non-homologous end joining (from Explanatory Sentence 6)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Loss of BRCA2, Chromosome breakage)\\n--------\\nImplies(C, And(D, E))\\nImplies(Inhibition of PARP, D & E)\\n--------\\nImplies(F, E)\\nImplies(PARP inhibitors, Double strand breaks)\\n--------\\nImplies(A, And(H, G))\\nImplies(Loss of BRCA2, G & H)\\n--------\\nImplies(I, And(J, K))\\nImplies(Trapping of PARP1 at sites of double strand breaks, J & K)\\n--------\\nImplies(Not(L), M)\\nImplies(Not(Single strand break repair), Replication-associated double strand breaks)\\n--------\\nImplies(F, And(N, O))\\nImplies(PARP inhibitors, N & O)\\n--------\\nImplies(Not(L), And(N, O))\\nImplies(Not(Single strand break repair), N & O)\\n--------\\nImplies(Not(L), M)\\nImplies(Not(Single strand break repair), Replication-associated double strand breaks)\\n--------\\nImplies(Not(L), And(N, O))\\nImplies(Not(Single strand break repair), N & O)\\n--------\\n\\nDerived Implications:\\nImplies(I, K)\\nImplies(Trapping of PARP1 at sites of double strand breaks, Increased toxicity)\\n--------\\nImplies(C, E)\\nImplies(Inhibition of PARP, Double strand breaks)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(Collapsed replication forks), Not(Inhibition of PARP))\\n--------\\nImplies(F, N)\\nImplies(PARP inhibitors, Defective homologous recombination repair)\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(Increased non-homologous end joining), Not(Trapping of PARP1 at sites of double strand breaks))\\n--------\\nImplies(F, O)\\nImplies(PARP inhibitors, Error-prone non-homologous end joining)\\n--------\\nImplies(Not(O), L)\\nImplies(Not(Error-prone non-homologous end joining), Single strand break repair)\\n--------\\nImplies(Not(O), Not(F))\\nImplies(Not(Error-prone non-homologous end joining), Not(PARP inhibitors))\\n--------\\nImplies(Not(H), Not(A))\\nImplies(Not(Genomic instability), Not(Loss of BRCA2))\\n--------\\nImplies(C, D)\\nImplies(Inhibition of PARP, Collapsed replication forks)\\n--------\\nImplies(Not(N), L)\\nImplies(Not(Defective homologous recombination repair), Single strand break repair)\\n--------\\nImplies(A, G)\\nImplies(Loss of BRCA2, Cancer development)\\n--------\\nImplies(Not(G), Not(A))\\nImplies(Not(Cancer development), Not(Loss of BRCA2))\\n--------\\nImplies(Not(N), Not(F))\\nImplies(Not(Defective homologous recombination repair), Not(PARP inhibitors))\\n--------\\nImplies(Not(L), N)\\nImplies(Not(Single strand break repair), Defective homologous recombination repair)\\n--------\\nImplies(Not(K), Not(I))\\nImplies(Not(Increased toxicity), Not(Trapping of PARP1 at sites of double strand breaks))\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(Double strand breaks), Not(Inhibition of PARP))\\n--------\\nImplies(Not(L), O)\\nImplies(Not(Single strand break repair), Error-prone non-homologous end joining)\\n--------\\nImplies(I, J)\\nImplies(Trapping of PARP1 at sites of double strand breaks, Increased non-homologous end joining)\\n--------\\nImplies(A, H)\\nImplies(Loss of BRCA2, Genomic instability)\\n--------\\n'}"
        ]
    }
}